Raymond James Financial
ELTX icon

Raymond James Financial’s Elicio Therapeutics ELTX Stock Holding History

Raymond James Financial’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.7K Buy
12,720
+1,620
+15% +$16.3K ﹤0.01% 5262
2026
Q1 		$119K Buy
+11,100
New +$107K ﹤0.01% 5002
2025
Q3 		– Sell
-6,000
Closed -$46.3K – 5501
2025
Q2 		$46.3K Buy
+6,000
New +$37.3K ﹤0.01% 5211

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Raymond James Financial's ELTX Position: Q2 2026 in Review

Raymond James Financial increased its Elicio Therapeutics (ELTX) stake by 15% in Q2 2026, buying an estimated $16.3K and bringing the position to 12,720 shares worth $49.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5262.

Raymond James Financial first reported a position in ELTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $119K in Q1 2026. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Raymond James Financial held 12,720 shares of Elicio Therapeutics worth $49.7K as of Q2 2026.
  • Raymond James Financial bought 1,620 Elicio Therapeutics shares in Q2 2026, an estimated $16.3K.
  • Elicio Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5262 holding.
  • Raymond James Financial first reported a position in Elicio Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Elicio Therapeutics position peaked at $119K in Q1 2026.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.